There are currently 84 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
NCT03258567
Recruiting
Background: The drug Nivolumab has been approved to treat some cancers. Researchers want to see if it can slow the growth of other cancers. They want to study its effects on cancers that may have not responded to chemotherapy or other treatments. Objectives: To see if Nivolumab slows the growth of some types of cancer or stops them from getting worse. To test the safety of the drug. Eligibility: People 12 and older who have Epstein-Barr Virus (EBV)-positive lymphoproliferative disorders or... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/23/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Epstein-Barr Virus Infections, Lymphoma, Lymphoproliferative Disorder, Disorders, Lymphoproliferative
Register for Updates
A Study of Mosunetuzumab in People With Follicular Lymphoma
NCT05389293
Recruiting
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations
Conditions: Follicular Lymphoma, Lymphoma
Register for Updates
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
NCT05495464
Recruiting
To learn if giving acalabrutinib, rituximab, and brexucabtagene autoleucel to patients with previously untreated high-risk mantle cell lymphoma (MCL) can help to control the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma, Mantle Cell Lymphoma
Register for Updates
Dietary and Topical Magnesium Replacement or Supplementation in Patients With Lymphoma
NCT05294367
Recruiting
This early phase I trial investigates the effect of dietary and topical magnesium replacement on magnesium blood levels in patients with lymphoma. Magnesium is an element in the body that is important to cell health. The body cannot make magnesium and it typically comes from the food we eat. In patients who are ill, magnesium is often replaced intravenously (IV) through a vein or by mouth. This study may help researchers find out if being on a magnesium rich diet and using a magnesium lotion on... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Lymphoma
Register for Updates
A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma
NCT04571138
Recruiting
Patients with relapsed or refractory leukemia or lymphoma are often refractory to further chemotherapy. In this study, the investigators will attempt to use T cells obtained directly from the patient, which can be genetically engineered to express a chimeric antigen receptor (CAR). The CAR used in this study can recognize CD22, a protein expressed on the surface of leukemia and lymphoma cells. The phase 1 part of this study will determine the safety and appropriate dose level of these CAR T cell... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
04/15/2025
Locations: Children's Hospital Los Angeles, Los Angeles, California +4 locations
Conditions: Leukemia, Lymphoma
Register for Updates
Vaccine Responses in Patients With B Cell Malignancies
NCT05170399
Recruiting
Background: People with B cell malignancies (blood cancers) often cannot mount a full immune response to infections or certain vaccines. Bruton tyrosine kinase inhibitors (BTKis), which are used to treat blood cancers, may also negatively affect a person s response to certain vaccines. Researchers want to learn more about vaccine responses in people with certain types of blood cancers. The findings may help develop better vaccine strategies for people with these cancers. Objective: To learn h... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
04/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/31/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +27 locations
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
NCT03856216
Recruiting
The goal of this phase II clinical study is to learn about the safety of inotuzumab ozogamicin when given with fludarabine, with or without bendamustine, melphalan, and rituximab before and after a stem cell transplant. Researchers also want to learn if inotuzumab ozogamicin when given after a stem cell transplant can help control leukemia and lymphoma. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a chemotherapy drug called ozogamicin. Inotuzumab attaches to CD22-... Read More
Gender:
ALL
Ages:
Between 12 years and 75 years
Trial Updated:
03/26/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Lymphocytic Neoplasm, Lymphoma
Register for Updates
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
NCT05683171
Recruiting
To find a recommended dose of valemetostat that can be given in combination with rituximab and lenalidomide to patients with follicular lymphoma. The safety and effects of this drug combination will also be studied
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
UPLYFT For Lymphoma Survivors
NCT05080166
Recruiting
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lymphoma, Survivorship
Register for Updates
Longitudinal Sexual and Reproductive Health Study of Women with Breast Cancer and Lymphoma
NCT01788839
Recruiting
The purpose of this study is to see how cancer treatment affects sexual and reproductive function. The patient will also be asked to participate in blood draws to see if and how cancer treatment affects the ovaries and the ability to have children (fertility). These blood draws are optional and the patient can still participate in the questionnaire portion of the study even if they choose not to have their blood drawn.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/24/2025
Locations: Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey +6 locations
Conditions: Breast Cancer, Lymphoma, Hodgkin's Lymphoma
Register for Updates
Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers
NCT05663502
Recruiting
This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may help doctors to learn how are biologic or genetic factors related to HIV and cancers that occur commonly in people living with HIV.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: UC San Diego Moores Cancer Center, La Jolla, California +6 locations
Conditions: Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
Register for Updates